7.23

0.41% -0.03

Nanobiotix ADR (NBTX)

Overview News Price History Discussions Forecast

Nanobiotix ADR stock is currently priced at $7.23, with a 24-hour trading volume of 1,741. It has seen a -0.41% decreased in the last 24 hours and a +34.39% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $7.34 pivot point. If it approaches the $7.18 support level, significant changes may occur.

Previous Close:

$7.26

Open:

$7.22

24h Volume:

1,741

Market Cap:

$340.61M

Revenue:

$27,600

Net Income/Loss:

$-62.02M

P/E Ratio:

-4.0797

EPS:

-1.7722

Net Cash Flow:

$-39.23M

1W Performance:

+9.55%

1M Performance:

+34.39%

6M Performance:

+18.23%

1Y Performance:

+44.60%

1D Range:

$7.1901

$7.41

52W Range:

$4.55

$11.00

Nanobiotix ADR Stock (NBTX) Company Profile

Name

Nanobiotix ADR

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

33 1 40 26 04 70

Address

60 rue de Wattignies, Paris

Employee

Twitter

Next Earnings Date

2024-05-22

Latest SEC Filings

NBTX's Discussions on Twitter

Nanobiotix ADR Stock (NBTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-06-21	Initiated	Evercore ISI	Outperform

Nanobiotix ADR Stock (NBTX) Latest News

Nanobiotix Announces Latest Share and Voting Rights Update - TipRanks.com - TipRanks

TipRanks

Nanobiotix Prepares to Unveil Q1 2024 Results - TipRanks.com - TipRanks

TipRanks

Nanobiotix's NBTXR3 Enters Phase 2 Lung Cancer Study - TipRanks.com - TipRanks

TipRanks

Nanobiotix's Revenue at Risk: The High Stakes of Sole Dependence on Janssen Partnership - TipRanks.com - TipRanks

TipRanks

CarMax Reports Downbeat Earnings, Joins Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Benzinga

Nanobiotix Sa ADR Updates Share Capital Info - TipRanks.com - TipRanks

TipRanks

Nanobiotix ADR Stock (NBTX) Financials Data

Nanobiotix ADR (NBTX) Revenue 2024

NBTX reported a revenue (TTM) of $27.60 thousand for the quarter ending June 30, 2021.

Nanobiotix ADR (NBTX) Net Income 2024

NBTX net income (TTM) was -$62.02 million for the quarter ending June 30, 2023, a -18.86% decrease year-over-year.

Nanobiotix ADR (NBTX) Cash Flow 2024

NBTX recorded a free cash flow (TTM) of -$39.23 million for the quarter ending June 30, 2023, a -9.77% decrease year-over-year.

Nanobiotix ADR (NBTX) Earnings per Share 2024

NBTX earnings per share (TTM) was -$1.7722 for the quarter ending June 30, 2023, a -9.33% decline year-over-year.

Nanobiotix SA operates as a clinical-stage nanomedicine company for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer hafnium oxide for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France.